Wahlstrøm K L, Bjerrum E, Gögenur I, Burcharth J, Ekeloef S
Department of Surgery, Centre for Surgical Science, Zealand University Hospital, Koege, Denmark.
BJS Open. 2021 Mar 5;5(2). doi: 10.1093/bjsopen/zraa026.
Remote ischaemic preconditioning (RIPC) has been shown to have a protective role on vital organs exposed to reperfusion injury. The aim of this systematic review was to evaluate the effects of non-invasive RIPC on clinical and biochemical outcomes in patients undergoing non-cardiac surgery.
A systematic literature search of PubMed, EMBASE, Scopus, and Cochrane databases was carried out in February 2020. RCTs investigating the effect of non-invasive RIPC in adults undergoing non-cardiac surgery were included. Meta-analyses and trial sequential analyses (TSAs) were performed on cardiovascular events, acute kidney injury, and short- and long-term mortality.
Some 43 RCTs including 3660 patients were included. The surgical areas comprised orthopaedic, vascular, abdominal, pulmonary, neurological, and urological surgery. Meta-analysis showed RIPC to be associated with fewer cardiovascular events in non-cardiac surgery (13 trials, 1968 patients, 421 events; odds ratio (OR) 0.68, 95 per cent c.i. 0.47 to 0.96; P = 0.03). Meta-analyses of the effect of RIPC on acute kidney injury (12 trials, 1208 patients, 211 events; OR 1.14, 0.78 to 1.69; P = 0.50; I2 = 9 per cent), short-term mortality (7 trials, 1239 patients, 65 events; OR 0.65, 0.37 to 1.12; P = 0.12; I2 = 0 per cent), and long-term mortality (4 trials, 1167 patients, 9 events; OR 0.67, 0.18 to 2.55; P = 0.56; I2 = 0 per cent) showed no significant differences for RIPC compared with standard perioperative care in non-cardiac surgery. However, TSAs showed that the required information sizes have not yet been reached.
Application of RIPC to non-cardiac surgery might reduce cardiovascular events, but not acute kidney injury or all-cause mortality, but currently available data are inadequate to confirm or reject an assumed intervention effect.
远程缺血预处理(RIPC)已被证明对遭受再灌注损伤的重要器官具有保护作用。本系统评价的目的是评估非侵入性RIPC对接受非心脏手术患者的临床和生化结局的影响。
2020年2月对PubMed、EMBASE、Scopus和Cochrane数据库进行了系统的文献检索。纳入了调查非侵入性RIPC对接受非心脏手术的成年人影响的随机对照试验(RCT)。对心血管事件、急性肾损伤以及短期和长期死亡率进行了荟萃分析和试验序贯分析(TSA)。
共纳入约43项RCT,包括3660例患者。手术领域包括骨科、血管、腹部、肺部、神经和泌尿外科手术。荟萃分析显示,RIPC与非心脏手术中较少的心血管事件相关(13项试验,1968例患者,421例事件;比值比(OR)0.68,95%置信区间0.47至0.96;P = 0.03)。对RIPC对急性肾损伤(12项试验,1208例患者,211例事件;OR 1.14,0.78至1.69;P = 0.50;I² = 9%)、短期死亡率(7项试验,1239例患者,65例事件;OR 0.65,0.37至1.12;P = 0.12;I² = 0%)和长期死亡率(4项试验,1167例患者,9例事件;OR 0.67,0.18至2.55;P = 0.56;I² = 0%)影响的荟萃分析显示,与非心脏手术的标准围手术期护理相比,RIPC无显著差异。然而,TSA显示尚未达到所需的信息量。
将RIPC应用于非心脏手术可能会减少心血管事件,但不会减少急性肾损伤或全因死亡率,但目前可用的数据不足以证实或否定假定的干预效果。